KST-6051 Receives FDA Fast Track Designation in KRAS-Mutant Solid Tumors

The FDA granted fast track designation to KST-6051, an oral pan-KRAS inhibitor, to accelerate development for treating advanced or metastatic solid tumors with KRAS mutations, including pancreatic, colorectal, and lung cancers.

This Wire brief sits within Fusion42's coverage of Biotech.